Why Is the SAA Blood Test Important for FMF Patients?
At a Glance
The Serum Amyloid A (SAA) blood test is crucial for FMF patients to detect silent inflammation between attacks. Keeping SAA levels consistently under 10 mg/L shows your medication is working and helps prevent serious long-term kidney complications like AA amyloidosis.
In this answer
3 sections
The Serum Amyloid A (SAA) blood test measures a specific protein produced by your liver in response to inflammation [1][2]. For people with Familial Mediterranean Fever (FMF), monitoring SAA is one of the most important aspects of managing the condition. Even when you are feeling well and not having a flare-up, your body may still be experiencing “silent” or subclinical inflammation [2][3]. If this silent inflammation goes unchecked, the liver continues to produce high levels of SAA, which can eventually build up in your organs and cause a severe complication called AA amyloidosis [2][3]. The clinical goal of FMF treatment is to keep your SAA level under 10 mg/L during your attack-free periods [3][4][5].
Why is SAA More Important than CRP or ESR?
If you have FMF, you are likely familiar with routine inflammation tests like C-Reactive Protein (CRP) and Erythrocyte Sedimentation Rate (ESR). While these are helpful, SAA provides a more precise and critical picture of your health for two main reasons:
- Greater Sensitivity: SAA is more sensitive than both CRP and ESR for detecting low-level, silent inflammation during the periods when you feel totally fine [3][6].
- Direct Link to Amyloidosis: While CRP and ESR simply signal that inflammation is happening somewhere in the body, SAA is the actual protein responsible for the most serious long-term risk of FMF [2]. When inflammation stays high, the excess SAA proteins can clump together into insoluble “amyloid fibrils” [2][7]. These fibrils can settle in your tissues—most commonly the kidneys—causing permanent damage known as secondary (AA) amyloidosis [2][8].
The Danger of “Silent” Inflammation
A common misconception is that if you aren’t experiencing FMF attacks, your disease is fully controlled. However, prolonged elevation of SAA levels between attacks proves that underlying inflammation is still active [2][6].
Because high SAA levels during these quiet periods directly correlate with an increased risk of progressive kidney injury and amyloid buildup, checking your blood when you aren’t having an attack is just as important as managing your active flares [6][9].
How Often Should You Be Tested?
While standard medical guidelines do not define a rigid, universal schedule for checking SAA, routine monitoring is an essential part of the “treat-to-target” approach in managing FMF [3][10]. Your doctor will establish a personalized testing schedule—often checking every few months—to ensure your medication is effectively controlling your disease [11][12].
Understanding Your Target Goal
When your doctor orders an SAA test, they are looking to see if your daily medication (such as colchicine) is effectively suppressing your underlying inflammation [13][14].
- The Goal: A widely accepted therapeutic target in FMF is keeping SAA levels consistently below 10 mg/L [3][5].
- Adjusting Treatment: If your SAA levels remain above this threshold between attacks, it strongly suggests your current medication dosage may not be fully protecting your organs [2][14]. In these cases, your doctor may recommend adjusting your colchicine dose or exploring other treatments, such as biologic medications (like IL-1 inhibitors, including anakinra or canakinumab), to safely bring your SAA back into the target range [15][16][17].
It is important to note that SAA is a highly sensitive marker that can spike temporarily due to everyday infections, like a cold or the flu [18]. For this reason, your doctor will look at the long-term trend of your SAA levels rather than a single isolated high result [18].
Common questions in this guide
Why is the SAA blood test more important than CRP or ESR for FMF?
What is the target SAA level for someone with Familial Mediterranean Fever?
What happens if my SAA levels stay high between FMF attacks?
Can a common cold affect my SAA blood test results?
Questions for Your Doctor
4 questions
- •What is my most recent SAA level, and is it currently under the 10 mg/L goal?
- •Based on my personal risk factors and medical history, how frequently should we be scheduling my SAA blood tests?
- •If my SAA levels remain consistently high despite my daily colchicine, what are our next steps for adjusting my medication or exploring biologic options?
- •Are there any early signs of kidney involvement or amyloidosis that we should be screening for alongside my routine SAA blood tests?
Questions for You
3 questions
- •Have I been feeling completely well between FMF attacks, or am I noticing subtle signs of inflammation like mild joint stiffness or fatigue?
- •How consistently am I taking my daily colchicine, and could missed doses be contributing to higher underlying inflammation?
- •Have I had any recent, everyday infections (like a cold or the flu) that might temporarily affect my upcoming SAA test results?
Related questions
References
References (18)
- 1
Serum amyloid A inhibits dendritic cell differentiation by suppressing GM-CSF receptor expression and signaling.
Kim JC, Jung YS, Lee HY, et al.
Experimental & molecular medicine 2017; (49(8)):e369 doi:10.1038/emm.2017.120.
PMID: 28857084 - 2
Amyloidosis and Glomerular Diseases in Familial Mediterranean Fever.
Siligato R, Gembillo G, Calabrese V, et al.
Medicina (Kaunas, Lithuania) 2021; (57(10)) doi:10.3390/medicina57101049.
PMID: 34684086 - 3
The Value of Serum Amyloid A Levels in Familial Mediterranean Fever to Identify Occult Inflammation During Asymptomatic Periods.
Çakan M, Karadağ ŞG, Tanatar A, et al.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2021; (27(1)):1-4 doi:10.1097/RHU.0000000000001134.
PMID: 31524848 - 4
Concordance between CRP and SAA in familial Mediterranean fever during attack-free period: A study of 218 patients.
Stankovic Stojanovic K, Hentgen V, Fellahi S, et al.
Clinical biochemistry 2017; (50(4-5)):206-209 doi:10.1016/j.clinbiochem.2016.11.008.
PMID: 27838405 - 5
The Relationship Among the Level of Serum Amyloid A, High-Density Lipoprotein and Microalbuminuria in Patients With Familial Mediterranean Fever.
Uslu AU, Aydin B, Icagasıoğlu IS, et al.
Journal of clinical laboratory analysis 2016; (30(6)):1003-1008 doi:10.1002/jcla.21971.
PMID: 27094695 - 6
Serum Amyloid A Level in Egyptian Children with Familial Mediterranean Fever.
Lofty HM, Marzouk H, Farag Y, et al.
International journal of rheumatology 2016; (2016()):7354018 doi:10.1155/2016/7354018.
PMID: 28070191 - 7
Amyloid A Amyloidosis.
Gaffney PM
Veterinary pathology 2017; (54(1)):5-8 doi:10.1177/0300985816677150.
PMID: 27879441 - 8
Familial Mediterranean fever: overview of pathogenesis, clinical features and management.
Migita K, Asano T, Sato S, et al.
Immunological medicine 2018; (41(2)):55-61 doi:10.1080/13497413.2018.1481579.
PMID: 30938266 - 9
Relationship between clinical findings and genetic mutations in patients with familial Mediterranean fever.
Kilic A, Varkal MA, Durmus MS, et al.
Pediatric rheumatology online journal 2015; (13()):59 doi:10.1186/s12969-015-0057-1.
PMID: 26759267 - 10
French protocol for the diagnosis and management of familial Mediterranean fever.
Georgin-Lavialle S, Savey L, Cuisset L, et al.
La Revue de medecine interne 2023; (44(11)):602-616 doi:10.1016/j.revmed.2023.10.441.
PMID: 37903671 - 11
Arterial stiffness in Familial Mediterranean Fever: correlations with disease-related parameters and colchicine treatment.
Sgouropoulou V, Stabouli S, Trachana M
Clinical rheumatology 2019; (38(9)):2577-2584 doi:10.1007/s10067-019-04601-6.
PMID: 31127463 - 12
What is the best acute phase reactant for familial Mediterranean fever follow-up and its role in the prediction of complications? A systematic review.
Erer B, Demirkaya E, Ozen S, Kallinich T
Rheumatology international 2016; (36(4)):483-7 doi:10.1007/s00296-015-3413-z.
PMID: 26712372 - 13
Infections and AA amyloidosis: An overview.
Deshayes S, Aouba A, Grateau G, Georgin-Lavialle S
International journal of clinical practice 2021; (75(6)):e13966 doi:10.1111/ijcp.13966.
PMID: 33368925 - 14
Secondary, AA, Amyloidosis.
Papa R, Lachmann HJ
Rheumatic diseases clinics of North America 2018; (44(4)):585-603 doi:10.1016/j.rdc.2018.06.004.
PMID: 30274625 - 15
[INTERLEUKIN 1 INHIBITORS--A NEW HORIZON IN THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER].
Shouval R, Livneh A, Ben-Zvi I
Harefuah 2015; (154(11)):716-9, 741.
PMID: 26821505 - 16
Long-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients.
Atas N, Eroglu GA, Sodan HN, et al.
Clinical and experimental rheumatology 2021; (39 Suppl 132(5)):30-36 doi:10.55563/clinexprheumatol/815tdt.
PMID: 34251317 - 17
Anti-interleukin-1 treatment among patients with familial Mediterranean fever resistant to colchicine treatment. Retrospective analysis.
Sargin G, Kose R, Senturk T
Sao Paulo medical journal = Revista paulista de medicina 2019; (137(1)):39-44 doi:10.1590/1516-3180.2018.0311101218.
PMID: 31116269 - 18
Serum amyloid A as a biomarker in differentiating attacks of familial Mediterranean fever from acute febrile infections.
Çakan M, Aktay Ayaz N, Keskindemirci G, et al.
Clinical rheumatology 2020; (39(1)):249-253 doi:10.1007/s10067-019-04765-1.
PMID: 31485845
This page provides educational information about SAA blood testing in Familial Mediterranean Fever. Always consult your healthcare provider to interpret your specific lab results and determine your proper treatment plan.
Get notified when new evidence is published on Familial Mediterranean fever.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.